CD274 and neoplasm: Cancer cell-derived EVs, which usually express programmed death ligand 1 (PD-L1) on their surface, are able to bind to PD-1 receptors on T cells and inhibit T cell activation and proliferation, thus weakening the immune system’s ability to recognise and clear tumour cells.